Immunic is the specialist for selective oral drugs in immunology. As a clinical stage company, we deliver clinical proof-of-concept for best-in-class therapies of Th1 and Th17 mediated chronic inflammatory diseases.
Immunic AG is based in the Munich biotech hub Martinsried and currently develops two products for the treatment of chronic inflammatory diseases including e.g. IBD and psoriasis. IMU-838 will be tested in a phase IIb trial in patients suffering from ulcerative colitis beginning of 2018. IMU-366 is a best-in-class inverse agonist of the nuclear receptor ROR gamma-t and currently in advanced preclinical stage.
Immunic enters into a global option and license agreement with Daiichi Sankyo
Downloads 20181105__Immunic_Option_and_License_Agreement_Daiichi_Sankyo_EN File size: 209 KB 20181105__Immunic_Option_and_License_Agreement_Daiichi_Sankyo_DE File size: 219 KB Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel ...
Read More
Read More
Immunic Reports Start of Enrollment into Clinical Phase 2 Study with IMU-838 in Patients with Ulcerative Colitis
Downloads 20180426_immunic_IND_en_final File size: 185 KB 20180426_immunic_uc_de_final File size: 186 KB First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oral investigational drug IMU-838, a best-in-class DHODH inhibitor ...
Read More
Read More
FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis
Downloads 20180111_immunic_IND_en File size: 181 KB 20180111_immunic_IND_de File size: 183 KB FDA has granted IND approval for Immunic’s oral investigational drug IMU-838 Active IND allows Immunic to proceed with Phase ...
Read More
Read More